Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FUSN

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Advanced Chart

Key Stats

Today's Range
$21.55
$21.55
50-Day Range
$21.38
$21.55
52-Week Range
$2.31
$21.60
Volume
N/A
Average Volume
1.69 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FUSN Stock News Headlines

Fusion Finance Ltd (FUSN)
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Fusion Pharma (FUSN) Earnings Dates & Reports
See More Headlines

FUSN Stock Analysis - Frequently Asked Questions

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.13. The firm had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%.

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FUSN
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-94,900,000.00
Net Margins
-4,136.55%
Pretax Margin
-5,084.07%

Debt

Sales & Book Value

Annual Sales
$2.07 million
Price / Cash Flow
N/A
Book Value
$3.07 per share
Price / Book
7.02

Miscellaneous

Free Float
78,468,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
-0.69
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:FUSN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners